Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Bornhauser M, et al. Among authors: deeg hj. Blood. 2003 Aug 1;102(3):820-6. doi: 10.1182/blood-2002-11-3567. Epub 2003 Apr 3. Blood. 2003. PMID: 12676781 Free article. Clinical Trial.
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Jurado M, et al. Among authors: deeg hj. Biol Blood Marrow Transplant. 2002;8(3):161-9. doi: 10.1053/bbmt.2002.v8.pm11939606. Biol Blood Marrow Transplant. 2002. PMID: 11939606 Free article. Clinical Trial.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Deeg HJ, et al. Blood. 2002 Aug 15;100(4):1201-7. doi: 10.1182/blood-2002-02-0527. Blood. 2002. PMID: 12149198 Free article. Clinical Trial.
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR. Deeg HJ, et al. Blood. 2003 Dec 1;102(12):3912-8. doi: 10.1182/blood-2003-06-1856. Epub 2003 Aug 14. Blood. 2003. PMID: 12920019 Free article. Clinical Trial.
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R. Nash RA, et al. Among authors: deeg hj. Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505. doi: 10.1016/j.bbmt.2005.03.006. Biol Blood Marrow Transplant. 2005. PMID: 15983549 Free article. Clinical Trial.
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Platzbecker U, et al. Among authors: deeg hj. Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25. doi: 10.1016/j.bbmt.2008.08.006. Biol Blood Marrow Transplant. 2008. PMID: 18940675 Free PMC article. Clinical Trial.
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FR. Pagel JM, et al. Among authors: deeg hj. Blood. 2009 Dec 24;114(27):5444-53. doi: 10.1182/blood-2009-03-213298. Epub 2009 Sep 28. Blood. 2009. PMID: 19786617 Free PMC article. Clinical Trial.
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornhäuser M, Itzykson R, Germing U, Beelen D, Ehninger G, Fenaux P, Deeg HJ, Adès L; German MDS Study; Cooperative Transplant Study Group; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies. Platzbecker U, et al. Among authors: deeg hj. Biol Blood Marrow Transplant. 2012 Sep;18(9):1415-21. doi: 10.1016/j.bbmt.2012.05.003. Epub 2012 May 11. Biol Blood Marrow Transplant. 2012. PMID: 22579634 Free PMC article.
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR. Slattery JT, et al. Among authors: deeg hj. Blood. 1997 Apr 15;89(8):3055-60. Blood. 1997. PMID: 9108427 Free article.
712 results